Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

Abstract Background Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic consequences. Here, we investigated whether patient treatment with the TKI sunitinib affected quantitative and qualitative...

Full description

Bibliographic Details
Main Authors: Bibian M. E. Tullemans, Sanne L. N. Brouns, Frauke Swieringa, Siamack Sabrkhany, Franchette W. P. J. van den Berkmortel, Natascha A. J. B. Peters, Peter de Bruijn, Stijn L. W. Koolen, Johan W. M. Heemskerk, Maureen J. B. Aarts, Marijke J. E. Kuijpers
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Cancer
Subjects:
Platelet count
Platelet aggregation
Sunitinib
Tyrosine kinase inhibitor
Renal cell carcinoma
cancer
Online Access:https://doi.org/10.1186/s12885-022-09676-0

Internet

https://doi.org/10.1186/s12885-022-09676-0

Similar Items